Determining the cost-effectiveness of preventing cardiovascular disease: Are estimates calculated over the duration of a clinical trial adequate?

Canadian Journal of Cardiology

Volumn 24, Issue 4, 2008, Pages 261-266

  Grover, Steven A ^a   Coupal, Louis ^a   Lowensteyn, Ilka ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Cardiovascular risk factors; Cholesterol; Cost effectiveness; Dyslipidemia; Health economics; Health outcomes; Hypertension

Indexed keywords

PLACEBO; RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACCURACY; ACUTE HEART INFARCTION; ARTICLE; CALIBRATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FORECASTING; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; KIDNEY FUNCTION; LIFE EXPECTANCY; META ANALYSIS; MICROALBUMINURIA; OUTCOMES RESEARCH; PROBABILITY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VALIDATION STUDY; AGED; CANADA; COMPARATIVE STUDY; DRUG COST; ECONOMICS; FEMALE; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; STATISTICS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALUE OF LIFE;

EID: 42949165120     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70174-0     Document Type: Article

References (32)

1. Fletcher GF, Balady GJ, Vogel RA. Preventive cardiology: How can we do better? Presented at the 33rd Bethesda Conference, Bethesda, Maryland, December 18, 2001. J Am Coll Cardiol 2002;40:579-651.
2. Lamy A, Yusuf S, Pogue J, Gafni A; Heart Outcomes Prevention Evaluation Investigators. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:960-5.
3. Carroll CA, Coen MM, Rymer MM. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. Clin Ther 2003;25:1248-61.
4. Carroll CA, Coen MM, Piepho RW. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients. Ann Pharmacother 2003;37:327-31.
5. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001;85:539-43.
6. Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ 2001;4:199-205.
7. Björholt I, Andersson FL, Kahan T, Ostergren J. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: A Swedish sub-study to the HOPE study. J Intern Med 2002;251:508-17.
8. Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics 1997;12:256-66. (Erratum in 1997;12:706).
9. Hart WM, Rubio-Terres C, Pajuelo F, González Juanatey JR. Cost-effectiveness of the treatment of heart failure with ramipril: A Spanish analysis of the AIRE study. Eur J Heart Fail 2002;4:553-8.
10. Schädlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998;14:653-69.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 2000;342:1376, 2000;342:748).
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9. (Erratum in 2000;356:860).
13. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
14. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-62. (Erratum in 1998;158:1228).
15. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
16. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: The lipid research clinics program prevalence study. Circulation 1980;61:302-15.
17. Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-7.
18. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005;95:586-91.
19. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.
20. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: A profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1969-74.
21. Resource Intensity Weights. Summary of Methodology, 1996/97. Canadian Institute for Health Information, 1996.
22. Régie de l'assurance maladie du Québec. Manuel des Médecins Spécialistes RAMQ. Québec: Régie de l'assurance maladie du Québec, 1996.
23. Ontario Ministry of Health. Schedule of benefits: Physician services, 1992. Toronto: Ontario Ministry of Health, 1992.
24. Statistics Canada. CANSIM Matrix 9440, Series L. Ottawa, 2002.
25. Statistics Canada. CANSIM Matrix P100200. Ottawa, 2002.
26. Statistics Canada. CANSIM Matrix L95705. Ottawa, 2002.
27. IMS Canada. Canadian Compuscript, November 2000. Point-Claire: IMS Canada, 2000.
28. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-62.
29. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997;349:1493-7.
30. Backhouse ME, Richter A, Gaffney L. Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events. J Med Econ 2005;3:97-109.
31. Schädlich PK, Brecht JD, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. Pharmacoeconomics 2004;22:955-73.
32. Hart WM, Rubio-Terrés C, Margalet Fernández I, González Juanatey JR. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain.] An Med Interna 2002;19:515-20.